Results 111 to 120 of about 42,681 (176)

Polo-like kinase 1-inhibitor co-complex structures via the surface-entropy reduction approach and a DARPin-assisted approach. [PDF]

Acta Crystallogr D Struct Biol
Eberspaecher U, Schmitz AA, Siemeister G, Bömer U, Bandeiras TM, Matias PM, Schulze VK, Hillig RC.   +7 more
europepmc   +1 more source

Polo-like kinase 1 (PLK1) O-GlcNAcylation is essential for dividing mammalian cells and inhibits uterine carcinoma. [PDF]

J Biol Chem, 2023
Yan S, Peng B, Kan S, Shao G, Xiahou Z, Tang X, Chen YX, Dong MQ, Liu X, Xu X, Li J.   +10 more
europepmc   +1 more source

Target Binding of Black Phosphorus Nanomaterial to Polo-Like Kinase 1 for Cancer Chemotherapy: A Mutual Selection of Nanomaterial and Protein. [PDF]

Exploration (Beijing)
Liu F, Li ZD, Zeng Y, Wang X, Liu Y, Li Q, Luo W, Suo X, Xu Y, Yuan F, Zhang D, Zhang W, Geng S, Yu XF, Zhang G, Li Y.   +15 more
europepmc   +1 more source

Effectiveness, safety and pharmacokinetics of Polo-like kinase 1 inhibitors in tumor therapy: A systematic review and meta-analysis. [PDF]

Front Oncol, 2023
Wei X, Song M, Huang C, Yu Q, Jiang G, Jin G, Jia X, Shi Z.   +7 more
europepmc   +1 more source

Erratum: Deciphering the performance of polo-like kinase 1 in triple-negative breast cancer progression according to the centromere protein U-phosphorylation pathway. [PDF]

Am J Cancer Res
Zhao S, Geng Y, Cao L, Yang Q, Pan T, Zhou D, Liu J, Shi Z, Zhang J.   +8 more
europepmc   +1 more source

The mitotic regulator polo-like kinase 1 as a potential therapeutic target for c-Myc-overexpressing canine osteosarcomas. [PDF]

Vet Comp Oncol, 2022
Gola C, Licenziato L, Accornero P, Iussich S, Morello E, Buracco P, Modesto P, Aresu L, De Maria R.   +8 more
europepmc   +1 more source

Pan-RAS inhibitors and polo-like kinase 1: promising targets in colorectal cancer. [PDF]

Oncogene
Jayachandran P, Elliott A, Soni S, Battaglin F, Mittal P, Algaze S, Lo JH, Yang Y, Ashouri K, Roussos Torres ET, Zhang W, Millstein J, Zhang L, Yu J, Lenz HJ.   +14 more
europepmc   +1 more source

Inhibition of Polo-like kinase 1 (PLK1) triggers cell apoptosis via ROS-caused mitochondrial dysfunction in colorectal carcinoma. [PDF]

J Cancer Res Clin Oncol, 2023
Feng Y, Li T, Lin Z, Li Y, Han X, Pei X, Fu Z, Wu Q, Shao D, Li C.   +9 more
europepmc   +1 more source

Polo-like Kinase 1 Activation Regulates Angiotensin II-Induced Contraction in Pudendal and Small Mesenteric Arteries from Mice. [PDF]

Cells
Moraes RA, Arishe OO, Pratt J, Wilczynski S, Dos Passos RR, Silva-Velasco DL, Gonçalves TT, Zhang T, Silva DF, Webb RC, Priviero F.   +10 more
europepmc   +1 more source

Structural Optimization and Anticancer Activity of Polo-like Kinase 1 (Plk1) Polo-Box Domain (PBD) Inhibitors and Their Prodrugs. [PDF]

ACS Pharmacol Transl Sci, 2023
Park JE, Lee H, Oliva P, Kirsch K, Kim B, Ahn JI, Alverez CN, Gaikwad S, Krausz KW, O'Connor R, Rai G, Simeonov A, Mock BA, Gonzalez FJ, Lee KS, Jacobson KA.   +15 more
europepmc   +1 more source